Results 1 to 10 of about 3,098 (189)

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease. [PDF]

J Clin Apher
ABSTRACT Elevated Lipoprotein(a) (Lp(a)) is a known independent cardiovascular risk factor. Lp(a) Lipoprotein Apheresis (LA) substantially reduces the number of cardiovascular events. The effect of LA treatment in hemodialysis (HD) patients remains unknown. Retrospective analysis of nine patients undergoing LA and HD.
Röseler T, Kayser D, Schlieper G, Bernhardt WM.   +3 more
europepmc   +3 more sources

Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a) [PDF]

Scientific Reports
Lipoprotein apheresis (LA) is a therapeutic option for hyperlipoproteinemia(a) (hyper-Lp(a)) and atherosclerotic cardiovascular disease (ASCVD). LA improves blood rheology, reduces oxidative stress parameters and improves endothelial function.
Joanna Marlęga-Linert, Aleksandra Gąsecka, Edwin van der Pol, Agnieszka Kuchta, Krzysztof J. Filipiak, Marcin Fijałkowski, Marcin Gruchała, Rienk Nieuwland, Agnieszka Mickiewicz   +8 more
doaj   +4 more sources

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients [PDF]

Journal of Cardiovascular Development and Disease, 2018
Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an extremely high risk of developing cardiovascular events (CVE), especially after all other therapeutic options were not tolerated, or appeared not to be ...
Ulrich Julius
doaj   +4 more sources

Lipoprotein apheresis efficacy and challenges: single center experience [PDF]

Hematology, Transfusion and Cell Therapy, 2022
Introduction: Lipoprotein apheresis (LA) is an extracorporeal therapy which removes apolipoprotein B-containing particles from the circulation. We evaluated techniques and efficiency of lipoprotein apheresis procedures applied to patients with familial ...
Zehra Narlı Özdemir, Uğur Şahin, Yasin Yıldırım, Cansın Tulunay Kaya, Osman İlhan   +4 more
doaj   +2 more sources

Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia [PDF]

Frontiers in Medicine, 2023
BackgroundPreeclampsia is a common and serious pregnancy-induced disease, with potential severe maternal and fetal complications. Recently, an increased lipoprotein (a) (Lp[a]) concentration, an important factor in cardiovascular diseases (CVDs ...
Joanna Marlȩga-Linert, Katarzyna Wartecka-Zielińska, Dariusz Wydra, Marcin Fijałkowski, Marcin Gruchała, Agnieszka Mickiewicz   +5 more
doaj   +2 more sources

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a) [PDF]

Antioxidants, 2021
Aims: An abundance of epidemiological evidence demonstrates that elevated lipoprotein(a) (Lp(a)) represents a significant contributing risk factor towards the development of cardiovascular disease.
Tina Z. Khan, Adam Hartley, Dorian Haskard, Mikhail Caga-Anan, Dudley J. Pennell, Peter Collins, Mahmoud Barbir, Ramzi Khamis   +7 more
doaj   +2 more sources

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins [PDF]

Atherosclerosis Plus
Background and aims: Previous studies have shown that lipoprotein apheresis can modify the plasma lipidome and pro-inflammatory and pro-thrombotic lipid mediators.
Chaoxuan Wang, Anne Kaufmann, Nadja Kampschulte, Ulf Elbelt, Ursula Kassner, Elisabeth Steinhagen-Thiessen, Anne Pietzner, Christoph Schmöcker, Dev Datta, Tiziana Sanpietro, Nils Helge Schebb, Karsten-H. Weylandt, Nadine Rohwer   +12 more
doaj   +2 more sources

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients [PDF]

Orphanet Journal of Rare Diseases, 2021
Background Lipoprotein apheresis (LA) is considered as an add-on therapy for patients with familial hypercholesterolemia (FH). We aimed to analyze the data collected in the last 15 years from FH patients treated with LA, to elucidate the benefit of this ...
J. Víšek, M. Bláha, V. Bláha, M. Lášticová, M. Lánska, C. Andrýs, J. Duintjer Tebbens, Ivone Cristina Igreja e Sá, K. Tripská, M. Vicen, I. Najmanová, P. Nachtigal   +11 more
doaj   +2 more sources

Just not cosmesis! Role of low-density lipoprotein apheresis in familial hypercholesterolemia: Experience at a newly developed tertiary care institution in Northern India

Asian Journal of Transfusion Science, 2021
Familial hypercholesterolemia (FH) is characterized by an increase in plasma low-density lipoprotein-cholesterol (LDL-C) levels. It presents with tendon/skin xanthomas and premature atherosclerotic cardiovascular disease.
Daljit Kaur, Gita Negi, Rohit Walia, Sheetal Malhotra, Riti Bhatia, Sushant K Meinia, Saikat Mandal, Ashish Jain   +7 more
doaj   +2 more sources

Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B [PDF]

Journal of Lipid Research, 2000
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates ...
Klaus G. Parhofer, P. Hugh R. Barrett, Thomas Demant, Peter Schwandt   +3 more
doaj   +2 more sources